Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Alnylam Pharmaceuticals Inc (ALNY)  
$146.72 0.98 (0.66%) as of 4:30 Tue 4/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 123,030,000
Market Cap: 18.05(B)
Last Volume: 352,430 Avg Vol: 729,112
52 Week Range: $146.51 - $212.05
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  824
Guru Rank Value     : 0.5
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 46,855 76,855 119,258 247,093
Total Sell Value $7,107,715 $12,957,715 $20,984,393 $48,829,179
Total People Sold 6 7 8 9
Total Sell Transactions 11 12 24 35
End Date 2024-01-18 2023-10-17 2023-04-18 2022-04-18

   
Records found: 475
  Page 1 of 19  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchOff   •       –      –    2024-03-20 3 IO $0.00 $0 I/I 0 537 -1%     
   Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchOff   •       –      –    2024-03-20 3 IO $0.00 $0 D/D 0 12,881 -1%     
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2024-03-01 4 A $0.00 $0 D/D 7,741 27,219     -
   Garg Pushkal CMO & EVP Dev & Med Affairs   •       –      –    2024-03-01 4 A $0.00 $0 D/D 4,751 13,417     -
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2024-03-01 4 A $0.00 $0 D/D 23,754 71,882     -
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2024-03-01 4 A $0.00 $0 D/D 4,751 9,987     -
   Sharp Philip A Director   –       •      –    2024-02-29 4 AS $150.60 $4,540,071 D/D (30,000) 0 -2%     
   Sharp Philip A Director   –       •      –    2024-02-29 4 OE $59.25 $1,777,500 D/D 30,000 30,000     -
   Garg Pushkal CMO & EVP Dev & Med Affairs   •       –      –    2024-02-28 4 S $154.54 $89,145 D/D (574) 8,666 5%     
   Franchini Indrani Lall EVP, CLO & Secretary   •       –      –    2024-02-28 4 S $154.54 $51,095 D/D (329) 4,133 5%     
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2024-02-28 4 S $154.54 $77,805 D/D (501) 5,236 5%     
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2024-02-28 4 S $154.54 $455,357 D/D (2,932) 48,128 5%     
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2024-02-28 4 S $154.54 $89,145 D/D (574) 19,478 5%     
   Garg Pushkal CMO & EVP Dev & Med Affairs   •       –      –    2024-02-27 4 OE $0.00 $0 D/D 1,908 9,240     -
   Franchini Indrani Lall EVP, CLO & Secretary   •       –      –    2024-02-27 4 OE $0.00 $0 D/D 878 4,462     -
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2024-02-27 4 OE $0.00 $0 D/D 1,667 5,737     -
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2024-02-27 4 OE $0.00 $0 D/D 5,921 51,060     -
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2024-02-27 4 OE $0.00 $0 D/D 1,908 20,052     -
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2024-02-16 4 S $147.50 $149,099 D/D (1,007) 18,144 0%     
   Garg Pushkal CMO & EVP Dev & Med Affairs   •       –      –    2024-02-16 4 S $147.50 $193,666 D/D (1,308) 7,332 0%     
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2024-02-16 4 S $147.50 $149,397 D/D (1,009) 4,070 0%     
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2024-02-16 4 S $147.50 $1,040,885 D/D (7,030) 45,139 0%     
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2024-02-15 4 A $0.00 $0 D/D 3,278 19,151     -
   Garg Pushkal CMO & EVP Dev & Med Affairs   •       –      –    2024-02-15 4 A $0.00 $0 D/D 4,295 8,640     -
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2024-02-15 4 A $0.00 $0 D/D 3,278 5,079     -
  475 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 19
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us